Cabozantinib (BMS-907351)

Name: Cabozantinib (BMS-907351)
Brand: Selleck Chemicals
SKU: S1119
Rating: 5 (94 reviews)

For research use only.

Catalog No.S1119 Synonyms: XL184

94 publications

Cabozantinib (BMS-907351) Chemical Structure

CAS No. 849217-68-1

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.

Selleck's Cabozantinib (BMS-907351) has been cited by 94 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Discov, 2018, 8(7):836-849

PubMed: 29657135 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Discov, 2014, 4(7):816-27

PubMed: 24771846 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3635

PubMed: 34298852 ( click the link to review the publication )

Front Oncol, 2021, 11:663517

PubMed: 33954115 ( click the link to review the publication )

Sci Rep, 2021, 11(1):12466

PubMed: 34127734 ( click the link to review the publication )

Molecules, 2021, 26(16)4949

PubMed: 34443536 ( click the link to review the publication )

J Pharm Biomed Anal, 2021, 205:114343

PubMed: 34500236 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Angiogenesis, 2021, 10.1007/s10456-021-09771-z

PubMed: 33629198 ( click the link to review the publication )

Nat Commun, 2020, 1;11(1):2124

PubMed: 32358507 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.1610.2020

PubMed: 33148676 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )
Cancers (Basel), 2020, 12(12)E3816

PubMed: 33348809 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2838

PubMed: 33019652 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1401

PubMed: 32485915 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(8):1176-1188

PubMed: 32461304 ( click the link to review the publication )

Mol Cancer Res, 2020, 1176-1188

PubMed: None ( click the link to review the publication )

Dis Model Mech, 2020, dmm.047779

PubMed: 33318047 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Commun Biol, 2020, 3(1):776

PubMed: 33328556 ( click the link to review the publication )

NPJ Precis Oncol, 2020, 4:21

PubMed: 32802958 ( click the link to review the publication )

Life Sci, 2020, 247:117402

PubMed: 32035930 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2019, 101021/acsami9b20178

PubMed: 31816241 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(6):830-844

PubMed: 30929576 ( click the link to review the publication )

Int J Cancer, 2019, 145(7):1991-2001

PubMed: 30848481 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):43

PubMed: 30898150 ( click the link to review the publication )

Cell Death Dis, 2019, 10(3):201

PubMed: 30814510 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0043

PubMed: 31527225 ( click the link to review the publication )

Oncogenesis, 2019, 8(2):7

PubMed: 30647407 ( click the link to review the publication )
J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(9)

PubMed: 31027376 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Oncotarget, 2019,

PubMed: 30863492 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4821

PubMed: 30446652 ( click the link to review the publication )

Sci Rep, 2018, 8(1):4177

PubMed: 29520051 ( click the link to review the publication )

Cell Signal, 2018, 51:191-198

PubMed: 30075184 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Regen Eng Transl Med, 2018, 4(3):120-132

PubMed: 30417074 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 30038711 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(20):6239-6253

PubMed: 28698200 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 17(3):603-613

PubMed: 29237806 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1533-1542

PubMed: 28795691 ( click the link to review the publication )

Cell Signal, 2017, 29:138-149

PubMed: 27777072 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(7):473-483

PubMed: 28475408 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Anticancer Res, 2017, 37(11):6125-6132

PubMed: 29061793 ( click the link to review the publication )
Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2094-104

PubMed: 26893478 ( click the link to review the publication )

Cancer Lett, 2016, 376(2):218-25

PubMed: 27060207 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):122-32

PubMed: 25955731 ( click the link to review the publication )

Mol Imaging, 2015, 13(0):1-5

PubMed: 25248353 ( click the link to review the publication )

Chem Biol, 2015, 22(4):504-515

PubMed: 25865310 ( click the link to review the publication )

Nat Commun, 2014, 5:3116

PubMed: 24445538 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1471

PubMed: 25321478 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Liver Int, 2014, 10.1111/liv.12524

PubMed: 24621440 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:1107-23

PubMed: 25170251 ( click the link to review the publication )

Genes Genomics, 2014, 36(6):829-841

PubMed: 25530832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7945-59

PubMed: 25277206 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e627

PubMed: 23661005 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 377(1-2):1-6

PubMed: 23811235 ( click the link to review the publication )

Surgery, 2012, 152(6):1238-47

PubMed: 23158190 ( click the link to review the publication )

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description

Targets

VEGFR2/KDR ^[1] (Cell-free assay)	c-Met ^[1] (Cell-free assay)	Axl ^[1] (Cell-free assay)
0.035 nM	1.3 nM	7 nM

In vitro

XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. ^[1] XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
E98NT	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\kNE4xOS1zMDFOwG0>		M2DZfWROW09?	MXnJR\|UxRTh7IH7N	MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OESwNFYoRjJ\|NEi0NFA3RC:jPh?=
SNU-5	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Gw[2lEPTB;IEG5JI5O	M172U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
Hs746T	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUe0Xm16UUN3ME25Mlkhdk1?	NWLZbXJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
SNU-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3uU25KSzVyPUWyNlMhdk1?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
SNU-16	M2O3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPh[opkUUN3ME2xNVQ6KG6P	MkmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
MDA-MB-231	NH:0V3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo[3TWM2OD1iNkSyNUBvVQ>?	MorlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
U87MG	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nxOGlEPTB;MUi1NUBvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
H441	NWjpRWd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7FRW5bUUN3ME2yNVcxOCCwTR?=	NF3wT4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
H69	M{DoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEL2fmNKSzVyPUKwNlAxKG6P	M4XEO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
PC3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\FRYg4UUN3ME2xNFgxOCCwTR?=	NYrQU4w5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
MTC-TT	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonSTWM2OD1yLkC0JEshOC5yMzFOwG0>	M3LJTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
MZ-CRC	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\hNmlEPTB-IEWg{txO	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR5MEm5OUc,OjF2N{C5PVU9N2F-
TPC-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjoUlNMUUN3ME2wMlA3KCtiMD6wNkDPxE1?	M1\YU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
NIH-3T3/TPR-Met	NF7TTmpHfW6ldHnvckBie3OjeR?=				MWfJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCrbjDtc5V{\SCQSVitN3Q{N1SSUj3N[ZQh[2WubIOsJGlEPTBiPTCxJO69VS5?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7NkG0OEc,OjR7OU[xOFQ9N2F-
BA/F3	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NFT0SJFKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDWSWdHWjJiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjygS2k2OCB;IECuNFA{KM7:TT6=	M1rjVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BaF3	NEC3OGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2fsWlQ5KGi{cx?=		NYTmOVFsUW6qaXLpeIlwdiCxZjDUSWwu\nW\|ZXSgVoV1KFN6OUHBJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCZWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFEh\|ryPLh?=	M1Xpb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BA/F3	NG\LWVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnPsOFghcHK\|		MnXFTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViVFXMMYZ2e2WmIGLFWEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjB3IN88UU4>	NVi1[llLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
TT	MoruS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXmxNEBl[Xm\|		NFH0N5FKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkAyOCCmYYnzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMUKg{txONg>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BA/F3	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVq0PEBpenN?		MnzQTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHY5ODSPIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLki5JO69VS5?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BaF3	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXjlT3dKPDhiaILz		M33Jd2lvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIGLleEBXQDB2TDDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkmxJO69VS5?	NYDDZoo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
Nthy-ori 3-1	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		M4TpflExKGSjeYO=		MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOeIh6NW:{aTCzMVEh[2WubIOgZYZ1\XJiMUCg[IF6eyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTC0Mlk{KM7:TT6=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BAF3	MmGySpVv[3Srb36gZZN{[Xl?	NV74OmJsOC5yMTD0c{AyOCC3TR?=	MYGxJIhz		M12zeGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIIfpcIQhfHmyZTDS[ZQhMHWwa37ve44hd3KrZ3nuLUBxcG:\|cHjvdplt[XSrb36gZZQhYTFyNkKvXVkxPSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDheEAxNjBzIITvJFExKHWPIHHmeIVzKDFiaIKgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT	M2fl[mZ2dmO2aX;uJIF{e2G7		MWe0JIhzew>?		NWHwS4lnUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKFKHVDDDOlM1XyCvdYThcpQh[XRiWUmwOUBqdiCqdX3hckBVXCClZXzsd{BifCBzIIXNJIFnfGW{IESgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	M2HH[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BAF3	NVX2b3V6TnWwY4Tpc44h[XO\|YYm=	NXrxSJk2OC5yMTD0c{AyOCC3TR?=	NYjIWY1jOSCqch?=		NHfNXppKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDS[ZQhWzh7MVGgcZV1[W62IDj1cotvd3ewIH;ybYdqdilicHjvd5Bpd3K7bHH0bY9vKGG2IGmxNFYzN1l7MEWg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XRiMD6wNUB1dyBzMDD1UUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NGHteJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
BAF3	MlnqSpVv[3Srb36gZZN{[Xl?	NYHXXWJxOC5yMTD0c{AyOCC3TR?=	MXWxJIhz		Mm\ETY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHM5QTGDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDQUGNo[W2vYTDheEB[Pzh\|IHH0JFAvODFidH:gNVAhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MmH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BAF3	M17YfWZ2dmO2aX;uJIF{e2G7	MU[wMlAyKHSxIEGwJJVO	MkjSNUBpeg>?		NGPWSnZKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDS[ZQhWzh7MVGgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1cW:wIH;mJHNp[yCjdDDZN\|E4KGG2IECuNFEhfG9iMUCgeW0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT	NYn0V5hRTnWwY4Tpc44h[XO\|YYm=	NVrDTolSOSC2bzCxNEB2VQ>?	NVLMc4k1PCCqcoO=		NF7DVoZKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFzD[4FudWFicHjvd5Bpd3K7bHH0bY9vKGG2IGm3PFMh[XRiMTD0c{AyOCC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MmnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT	NWTjenA3TnWwY4Tpc44h[XO\|YYm=	MX2xJJRwKDFyIIXN	MUO0JIhzew>?		M{\GPGlvcGmkaYTpc44hd2ZiUlXUJGM3OzSZIH31eIFvfCCrbjDoeY1idiCWVDDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODJxWUKwOEBifCBzIITvJFExKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NGHvNoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT	MlPQSpVv[3Srb36gZZN{[Xl?	NFXKSmcyKHSxIEGwJJVO	MlyyOEBpenN?		M{PFXmlvcGmkaYTpc44hd2ZiUlXUJGM3OzSZIH31eIFvfCCrbjDoeY1idiCWVDDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIHH0JHQ{ODhxU{S3N{BifCBzIITvJFExKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT	MmTSSpVv[3Srb36gZZN{[Xl?	M4\DblEhfU1?			NFzmTnRKdmirYnn0bY9vKG:oIGLleE1lemm4ZX6gc45kd2enbnnjJJRz[W6\|Zn;ycYF1cW:wIH;mJIh2dWGwIGTUJINmdGy\|IHH0JFEhfU1iYomgd49nfCCjZ3HyJIF{e2G7	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT	Mn\1SpVv[3Srb36gZZN{[Xl?	NV35boVoOSC3TR?=	M{\hdVQhcHK\|		NXLrNXloUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKFKHVDDDOlM1XyCvdYThcpQh[XRiWUGwOlIhcW5iaIXtZY4hXFRiY3XscJMh[XRiMTD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT	NWK4T2dlSXCxcITvd4l{KGG\|c3H5	NHHsTJIyKHWP	MnfZPVYhcHK\|		MY\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFSWIHPlcIx{KGW6cILld5NqdmdiUnX0JGM3OzSZIH31eIFvfCCjdDCxJJVOKGGodHXyJFk3KGi{czDifUBidm6neHnuWk9RUSC\|dHHpcolv\y2kYYPl[EBndG:5IHP5eI9u\XS{aXOgZY5idHm\|aYO=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
PC3	M1nE[mZ2dmO2aX;uJIF{e2G7		NYXZfFBLOSC2bzCzJIhzew>?		M3;YbGlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEOyClZXzsd{BqdmO3YnH0[YQh\m:{IEGgeI8hOyCqcoOsJGlEPTBiPTCxMlkh\|ryPLh?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdzN{KwNUc,OjZ5MUeyNFE9N2F-
MDA-MB-231	NV7QU5NDTnWwY4Tpc44h[XO\|YYm=		NEKwb4syKHSxIEOgbJJ{		MnzITY5pcWKrdHnvckBw\iCDWFygdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKHSxIEOgbJJ{NCCLQ{WwJF0hPSEQvF2u	NXP2OI5MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3NVczODFpPkK2O\|E4OjBzPD;hQi=>
BAF3	MVnGeY5kfGmxbjDhd5NigQ>?		M2nIcVEhfG9iMzDodpM>		NY\wPFBGUW6qaXLpeIlwdiCxZjDGUHQ{KCi3bnvuc5dvKG:{aXfpckkheGixc4Doc5J6dGG2aX;uJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKDRkOgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKHSxIEOgbJJ{NCCLQ{WwJF0hPy53IN88UU4>	Ml[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MUeyNFEoRjJ4N{G3NlAyRC:jPh?=
MDA-MB-231	M3jXZWZ2dmO2aX;uJIF{e2G7		MYGxJJRwKDNiaILz		MVfJcohq[mm2aX;uJI9nKEuLVDCoeY5sdm:5bjDvdolocW5rIIDoc5NxcG:{eXzheIlwdiC2cnHud4Zm[3SnZDDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhOSC2bzCzJIhzeyxiSVO1NEA:KDR{IN88UU4>	Mnm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MUeyNFEoRjJ4N{G3NlAyRC:jPh?=
BA/F3	MnLwSpVv[3Srb36gZZN{[Xl?		MWi0PEBpenN?		NIXNSZJKdmirYnn0bY9vKG:oIFvEVkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFPlcIwhfGm2cnWg[4xwNWKjc3XkJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF2IN88UU4>	MlTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6N{S3OFEoRjJ4OEe0O\|QyRC:jPh?=
Sf21	NYLxTI1YTnWwY4Tpc44h[XO\|YYm=		MmGwNVUhdWmwcx?=		MofyTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJIh2dWGwIFvEVkBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB{MDDtbY5{KGK7IFjUVmYh[XO\|YYmsJGlEPTBiPTCwMlAyPiEQvF2u	NVi3eYE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4O\|Q4PDFpPkK2PFc1PzRzPD;hQi=>
BA/F3	M3uwTWZ2dmO2aX;uJIF{e2G7		NYG4Z5d2PDhiaILz		NX3vWGZRUW6qaXLpeIlwdiCxZjDLTWY2Si:URWSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCFZXzsJJRqfHKnIHfsc{1j[XOnZDDseY1qdmW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlE6KM7:TT6=	M1\2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe0O\|QyLz5{Nki3OFc1OTxxYU6=
BA/F3	NV;YXm9ZTnWwY4Tpc44h[XO\|YYm=		NIrkNJY1QCCqcoO=		NFzhSI5KdmirYnn0bY9vKG:oIFvJSlVDN1KHVDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KEOnbHygeIl1emViZ3zvMYJie2WmIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNVkh\|ryPLh?=	NHrEWFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki3OFc1OSd-Mk[4O\|Q4PDF:L3G+
BA/F3	NWD3dFBvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2flUVczKGi{cx?=		MlPRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJHRRWi2PZYSgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlAzOTlizszNMi=>	NHTN[HI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2PFg5QSd-MkewOlg5QDl:L3G+
Sf21	NHO3NXRHfW6ldHnvckBie3OjeR?=		MkWzOlAhdWmwcx?=		M1TJNWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBz\WOxbXLpcoFvfCCqdX3hckBTTVRiKE[1PEBz\XOrZIXld{kh\XiycnXzd4VlKGmwIHnud4VkfCCVZkKxJINmdGy\|IIXzbY5oKHCxbImoS4x2NFS7cjm0PlEh[XNic4Xid5Rz[XSnIHnuZ5Vj[XSnZDDmc5IhPjBibXnud{BjgSCHTFnTRUwhUUN3MDC9JFAvODB\|IN88UU4>	M4fTXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Sf21	Mn7BSpVv[3Srb36gZZN{[Xl?		NYfFUmZIPjBibXnudy=>		NVztUlQyUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC22YXfn[YQhemWlb33ibY5idnRiaIXtZY4hWkWWIG[4NFROKG23dHHueEApPjV6IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hcW6\|ZXP0JHNnOjFiY3XscJMhfXOrbnegdI9tgSiJbIWsWJlzMTR8MTDhd{B{fWK\|dILheIUhcW6ldXLheIVlKG[xcjC2NEBucW6\|IHL5JGVNUVODLDDJR\|UxKD1iMD64NVEh\|ryPLh?=	M2fmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
BaF3	NXvNeoU6TnWwY4Tpc44h[XO\|YYm=		MVK3NkBpenN?		NFfTfJNKdmirYnn0bY9vKG:oIFPDSGM3NVKHVDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCZWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLki4PUDPxE1w	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MUC2Okc,OjdzM{GwOlY9N2F-
BaF3	NYfzTHV1TnWwY4Tpc44h[XO\|YYm=		M4H2blczKGi{cx?=		M1HGdGlvcGmkaYTpc44hd2ZiQ1PER\|YuWkWWIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLhSlMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRk9ES0tvODDhd5NigSxiSVO1NEA:KDBwOEi5JO69VS5?	NF:3bmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN\|ExPjZ:L3G+
Ba/F3	MkSySpVv[3Srb36gZZN{[Xl?				NY\pSVFMUW6qaXLpeIlwdiCxZjDSSXQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEeLNUCgQUAxNjB5IN88UU4>	M1PRclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEG0OVYxLz5{N{ixOFU3ODxxYU6=
TT	NHOyUmRHfW6ldHnvckBie3OjeR?=				MknjTY5pcWKrdHnvckBw\iCURWSgR\|Y{PFdibYX0ZY51KGmwIHj1cYFvKFSWIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNlYh\|ryPLh?=	NUHKNG9SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVQ2PjBpPkK3PFE1PTZyPD;hQi=>
Ba/F3	MVvGeY5kfGmxbjDhd5NigQ>?				MWXJcohq[mm2aX;uJI9nKFKHVDDWPFA1VSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEeLNUCgQUAxNjd2IN88UU4>	NWnHZVhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVQ2PjBpPkK3PFE1PTZyPD;hQi=>
Nthy-ori 3-1	Mme3R5l1d3SxeHnjbZR6KGG\|c3H5				NYH6UZFLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVnSqeT3vdokhOy1zIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IEKuPVIh\|ryPLh?=	NH3Md4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixOFU3OCd-Mke4NVQ2PjB:L3G+
HepG2	NWnCWZB3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NV7s[W1sPzJiaILz		NX:1NGhQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xOTJizszNMi=>	NVrkR45YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVIyPTlpPkK4OFEzOTV7PD;hQi=>
EBC1	MnywRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHe3[\|M4OiCqcoO=		NUnHOldvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA2OTRizszNMi=>	NYPTPZpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVIyPTlpPkK4OFEzOTV7PD;hQi=>
H1299	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHHEVoc4OiCqcoO=		NWH3cWZiT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUDF{OUmgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDFwOUG5JO69VS5?	MlzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NUG5O\|koRjJ6NkWxPVc6RC:jPh?=
MCF7	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlLxO\|IhcHK\|		M3;HTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFIvQDh7IN88UU4>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O\|k9N2F-
A549	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mmq1O\|IhcHK\|		NW\oXW46T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPC5{MEWg{txONg>?	M3LVVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
T47D	NFHDOWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkPxO\|IhcHK\|		MoHLS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWFQ4TCClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gOE41PDhizszNMi=>	MmTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NUG5O\|koRjJ6NkWxPVc6RC:jPh?=
H460	NYTEd2kxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlHVO\|IhcHK\|		M2nXTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGg1PjBiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFUvPjZ7IN88UU4>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O\|k9N2F-
HuH7	M17qTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NF3BZo41QCCqcoO=		MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwM{S4JO69VS5?	NF30dWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC1O\|A1Oid-MkmwOVcxPDJ:L3G+
A498	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mmn6OFghcHK\|		NEL1ZlRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEiuOFU3KM7:TT6=	NEXYT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC1O\|A1Oid-MkmwOVcxPDJ:L3G+
NCI-H727	M1n3cmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUS0PEBpenN?		NHmwO3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPzJ5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyPC5yMTFOwG0v	M2PGPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEW3NFQzLz5{OUC1O\|A1OjxxYU6=
BAF3	MnLwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn7jO\|IhcHK\|		M33NT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegWHJRNU2HVDDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO\|YYmsJGlEPTBiPTCwMlAzPCEQvF2u	NW\jblJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFY1PTJpPkK5NVQ3PDV{PD;hQi=>
A549	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=	NVH3W3hnOTBidV2=	NYDJOnhHPzJiaILz		Ml30R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BifCBzMDD1UUBi\nSncjC3NkBpenNiYomgTY5kfWO7dHWgcIl3\S2lZXzsJIlu[WerbnegZY5idHm\|aYO=	NEjFNFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k3Oyd-Mkm0NFc6PjN:L3G+
A673	M1raVJFJXFNiYYPzZZk>				NUjyb5U4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NXrwV4pmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	M1y1Z5FJXFNiYYPzZZk>				NXnNVVg4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NXjLTmpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	MX;xTHRUKGG\|c3H5				NHjvVnhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	M{fNN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	M{OxNZFJXFNiYYPzZZk>				NH62bW5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MnO4dWhVWyCjc4PhfS=>				MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	M4SxWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NGi5bVdyUFSVIHHzd4F6				MkXBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	NH7KN5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	M1naVZFJXFNiYYPzZZk>				Mmq4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	NH\Pcpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MoLldWhVWyCjc4PhfS=>				MnvpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NH74Rpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NEXpRmNyUFSVIHHzd4F6				MmDndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	M2faZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NU\CPW91eUiWUzDhd5NigQ>?				NV6xdXZveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MlPEdWhVWyCjc4PhfS=>				MnrsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	M4ntOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NXXGeoVNeUiWUzDhd5NigQ>?				MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM>	NXftOFNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	MYTxTHRUKGG\|c3H5				MojCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{	NHPn[Jg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NEXwUmFyUFSVIHHzd4F6				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	NX\zbpd4eUiWUzDhd5NigQ>?				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NXmwfWNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MVHxTHRUKGG\|c3H5				NViyZ21xeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NVnKXmI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NYS2bpJmeUiWUzDhd5NigQ>?				NU\BUlh3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	Mlz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NHzTSnpyUFSVIHHzd4F6				MkDDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NXrjRmgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NGfjRmZyUFSVIHHzd4F6				MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	MoXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	Mon6dWhVWyCjc4PhfS=>				NYjaU2t3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	Ml;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	MmHQdWhVWyCjc4PhfS=>				Mn76dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	M13pVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NIj6SY1yUFSVIHHzd4F6				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTZY9{NTJiY3XscJM>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
EBC1	NIfsUI9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NEnaTo84OiCqcoO=		M3v2WmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNFQ5KM7:TT6=	MlXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
MKN45	MkDSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkH6O\|IhcHK\|		NF[1b3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAxPjlizszNMi=>	M4rI[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS4OlU1Lz5\|MEK0PFY2PDxxYU6=
SNU5	MkLXRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYC3NkBpenN?		NHPo[XZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPOWVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFEzOSEQvF2u	NELv[WY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK0PFY2PCd-M{CyOFg3PTR:L3G+
BAF3	NUnZTXI{TnWwY4Tpc44h[XO\|YYm=		Mlv5O\|IhcHK\|		NEPKdIVKdmirYnn0bY9vKG:oIGTQVk11[WepZXSgcYV1KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEG5PFYh\|ryPLh?=	MmP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
NCI-H460	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVLtWYZzPzJiaILz		MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA1ODFizszNMi=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2OE[1OEc,OzB{NEi2OVQ9N2F-
MGHU3	NUm1dlRjSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NY\VWJI1PzJiaILz		NFvheoNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3HTHU{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5	M1PBdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{C5OlcyLz5\|MEOwPVY4OTxxYU6=
RT112	Mn\vRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkW4O\|IhcHK\|		NUfNUmlHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSWFEyOiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfS=>	M4TNOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{C5OlcyLz5\|MEOwPVY4OTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-MET(Y1234/1235) / MET / p-EGFR(Y1068) / EGFR / p-Gab1(Y627) / Gab1 / p-AKT(S473) / p-ERK / p-EIF4E; PubMed: 29188469 Invest New Drugs MET kinase inhibitors but not emibetuzumab inhibited MET signaling pathway in Hs746t cells in vitro by western blot analysis. Hs746t cells were treated for 24 h with 133 nM (20 μg/ml) or 667 nM (100 μg/ml) emibetuzumab or MET kinase inhibitors (merestinib, PF04217903, crizotinib, cabozantinib) at 15.6, 62.5, 250 or 1000 nM. p-MET / p-ERK / p-AKT; PubMed: 29520051 Sci Rep Western blot analysis of cellular pathways modifications after CBZ 5 μM treatment in HOS, MG-63, Saos-2 and U-2 OS cells; (A) CBZ 5 μM inhibits c-MET phosphorilation after 1 hour of treatment; downstream ERK activation kinetic adopts a sigmoidal shape in all OS cell lines, whereas AKT activation is strongly inhibited in HOS, Saos-2 and U-2OS, but not in MG-63 cells.	29188469 29520051
Immunofluorescence	α-tubulin; PubMed: 29520051 Sci Rep Immunostaining of mitotic spindle in control and CBZ 5 μM treated HOS cells using a monoclonal antibody against α-tubulin (in green); white arrows indicate the mitotic spindle poles; control cells show normal bipolar spindles during metaphase formation, whereas treated cells show tripolar spindles during prometaphase (II), metaphase (III) and anaphase (IV); bar scale = 10 μm.	29520051
Growth inhibition assay	Cell viability; PubMed: 23661005 Cell Death Dis Cells were left untreated or were treated with 5, 7.5 or 10 μM cabozantinib (XL184). Seventy-two hours later viability was detected by MTT-assay and apoptosis by staining with annexinV-FITC followed by FACS-analysis.	23661005

In vivo

XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. ^[1] XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. ^[2] Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. ^[3]

Protocol

Cell Research:

^[2]

- Collapse

Cell lines: ST88-14, STS26T, and MPNST724
Concentrations: Dissolved in DMSO, final concentrations ~10 μM
Incubation Time: 48 hours
Method:
Cells are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: RIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
Dosages: ~60 mg/kg
Administration: Oral gavage
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (199.39 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Cabozantinib (BMS-907351) SDF

Molecular Weight	501.51
Formula	C₂₈H₂₄FN₃O₅
CAS No.	849217-68-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	XL184
Smiles	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04957160	Not yet recruiting	--	Advanced Renal Cell Carcinoma (aRCC)	Ipsen	September 4 2021	--
NCT04868773	Recruiting	Drug: Cabozantinib\|Drug: TAS-102	Colorectal Cancer\|Colorectal Carcinoma\|Metastatic Cancer\|CRC	University of California Irvine	July 2021	Phase 1
NCT04893785	Not yet recruiting	Drug: Cabozantinib and Temozolomide	Lung Neuroendocrine Neoplasm\|GEP Neuroendocrine Tumor	National Cancer Institute Naples	June 2021	Phase 2
NCT04804813	Recruiting	Drug: Cabozantinib	Renal Cell Carcinoma	Takeda	March 29 2021	--
NCT04631744	Recruiting	Drug: Cabozantinib	Prostate Cancer	Weill Medical College of Cornell University\|Exelixis	March 3 2021	Phase 2
NCT04300140	Recruiting	Drug: AVB-S6-500\|Drug: Cabozantinib (Cabo)	Clear Cell Renal Cell Carcinoma	Aravive Inc.	February 26 2021	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Pan VEGFR Inhibitors

Regorafenib (BAY 73-4506) : Pan-VEGFR inhibitor, VEGFR1/VEGFR2/VEGFR3, IC50=13 nM/4.2 nM/46 nM.
Most Potent VEGFR Inhibitor

Axitinib : VEGFR1, VEGFR2, VEGFR3, IC50=0.1 nM, 0.2 nM, 0.1-0.3 nM.
FDA-approved VEGFR Inhibitor

Axitinib : Approved by FDA for Renal Cell Carcinoma.
Classic VEGFR Inhibitor

Dovitinib (TKI-258, CHIR-258) : Multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM.

Related VEGFR Products

SU5402 ^New

SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.
Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506, Fluoro-Sorafenib, Resihance, Stivarga) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit (c-Kit), RET (c-RET) and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively. Regorafenib induces autophagy.
Axitinib (AG 013736)

Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Features:Superior as second-line therapy relative to sorafenib (current standard-of-care).
Nintedanib (BIBF 1120)

Nintedanib (BIBF 1120, Intedanib, Vargatef, Ofev) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.
Vandetanib (ZD6474)

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Lenvatinib (E7080)

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Lenvatinib (E7080) also inhibits FGFR1-4, PDGFR, Kit (c-Kit), RET (c-RET), and shows potent antitumor activities. Phase 3.
Pazopanib

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.
Pazopanib HCl (GW786034 HCl)

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces autophagic Type II cell death.

Features:A multi-kinase inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Cabozantinib (BMS-907351)